Xeljanz — Revenues:
Pfizer Xeljanz — Revenues: decreased by 44.4% to $180.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 40.6%, from $128.00M to $180.00M. Over 4 years (FY 2021 to FY 2025), Xeljanz — Revenues: shows a downward trend with a -18.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration and successful clinical adoption, while a decrease may signal increased competition from biosimilars or changes in clinical guidelines.
Detailed definition
This metric represents the total global net sales generated by a specific pharmaceutical product line used for the treat...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or therapeutic franchises at other large-cap pharmaceutical companies.
pfe_segment_xeljanz_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $586.00M | $610.00M | $721.00M | $372.00M | $430.00M | $502.00M | $492.00M | $237.00M | $469.00M | $503.00M | $493.00M | $194.00M | $303.00M | $321.00M | $350.00M | $128.00M | $322.00M | $313.00M | $324.00M | $180.00M |
| QoQ Change | — | +4.1% | +18.2% | -48.4% | +15.6% | +16.7% | -2.0% | -51.8% | +97.9% | +7.2% | -2.0% | -60.6% | +56.2% | +5.9% | +9.0% | -63.4% | +151.6% | -2.8% | +3.5% | -44.4% |
| YoY Change | — | — | — | — | -26.6% | -17.7% | -31.8% | -36.3% | +9.1% | +0.2% | +0.2% | -18.1% | -35.4% | -36.2% | -29.0% | -34.0% | +6.3% | -2.5% | -7.4% | +40.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's xeljanz — revenues:?
- Pfizer (PFE) reported xeljanz — revenues: of $180.00M in Q1 2026.
- How has Pfizer's xeljanz — revenues: changed year-over-year?
- Pfizer's xeljanz — revenues: increased by 40.6% year-over-year, from $128.00M to $180.00M.
- What is the long-term trend for Pfizer's xeljanz — revenues:?
- Over 4 years (2021 to 2025), Pfizer's xeljanz — revenues: has grown at a -18.4% compound annual growth rate (CAGR), from $2.46B to $1.09B.
- What does xeljanz — revenues: mean?
- The total revenue generated from sales of a specific immunology drug product.